NCT06844474

A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

A Phase II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-1826 for Injection in Patients With NSCLC

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is an open-label, multicenter Phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in patients with NSCLC.

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	SHR-1826；Adebrelimab；SHR-8068；Bevacizumab	Drug: Drug: SHR-1826 Administration by intravenous infusion for a cycle of 3 weeks. Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks. Drug: SHR-8068 Administration by intravenous infusion for a cycle of 6 weeks. Drug: Bevacizumab Administration by intravenous infusion for a cycle of 3 weeks.

Timeline

• Start date: 2025-03-07
• Primary completion: 2026-08-31
• Completion: 2028-02-29
• First posted: 2025-02-25
• Last updated: 2025-03-19

Locations

1 site across 1 country: China